官方服务：
资源简介：
Capecitabine with or without bevacizumab as maintenance therapy in metastatic colorectal cancer: A real-world retrospective study in Vietnamese patients
应用场景：
创建时间：
2025-01-01
相关数据集
The relative distribution and prevalence of cancer cases by type in the All of Us Research Program from self-reported survey data and electronic health record overall.
The relative distribution and prevalence of cancer cases by type in the All of Us Research Program from self-reported survey data and electronic health record overall.
NIAID Data Ecosystem40
SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib ...
These data support the main findings described in 'SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic...
B2FIND30
Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan
Objectives: This real-world study assessed the effectiveness and safety outcomes of initiating adalimumab and methotrexate (≥12 mg/week) with adjustable dosing in Japanese patients with early rheumato
Figshare2018-10-25 更新10
FORECAST 1. Feasibility of using Organoid Response to find Effective Treatments for patients with Colorectal cancer After failure of Standard Therapy
Interventions: This feasibility study involves the collection of fresh tumour tissue from patients with Metastatic Colorectal Cancer ( mCRC) for the purposes of establishing organoid model cultures.Pa
NIAID Data Ecosystem40
Dataset from A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen
Primary Objective:To assess efficacy aflibercept + 5-fluorouracil (5-FU)/levofolinate/irinotecan (FOLFIRI) by objective response rate (ORR).Secondary Objective:To assess the following:* safety profile
NIAID Data Ecosystem10
